|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5344760A
(en)
|
1991-06-03 |
1994-09-06 |
Ciba Corning Diagnostics Corp. |
Method of cancer detection
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6983227B1
(en)
|
1995-01-17 |
2006-01-03 |
Intertech Ventures, Ltd. |
Virtual models of complex systems
|
|
ATE483733T1
(de)
|
1995-06-14 |
2010-10-15 |
Univ California |
Hochaffine humane antikörper gegen tumorantigene
|
|
IL126303A
(en)
|
1996-03-27 |
2002-05-23 |
Genentech Inc |
ErbB3 ANTIBODIES
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
EP0912734B1
(en)
|
1996-07-12 |
2010-11-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
GB2336695A
(en)
|
1998-04-20 |
1999-10-27 |
Teamware Group Oy |
Modelling a work process
|
|
JP2002515511A
(ja)
|
1998-05-15 |
2002-05-28 |
イムクローン システムズ インコーポレイティド |
放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US6627196B1
(en)
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
EP2330219A3
(en)
|
2000-04-14 |
2011-11-23 |
Metabolon, Inc. |
Method for drug discovery, disease treatment and diagnosis using metabolomics
|
|
PT1282443E
(pt)
|
2000-05-19 |
2009-12-04 |
Genentech Inc |
Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
US6871171B1
(en)
|
2000-10-19 |
2005-03-22 |
Optimata Ltd. |
System and methods for optimized drug delivery and progression of diseased and normal cells
|
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
DE60234094D1
(de)
*
|
2001-05-11 |
2009-12-03 |
Ludwig Inst For Cancer Res Ltd |
Spezifische bindungsproteine und ihre verwendung
|
|
US7612042B2
(en)
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
|
WO2003011897A1
(en)
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
|
JP2005508887A
(ja)
|
2001-08-03 |
2005-04-07 |
コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション |
Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法
|
|
US7662374B2
(en)
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
HUP0401903A3
(en)
|
2001-10-19 |
2008-07-28 |
Pharma Mar |
Improved use of et-743 in cancer thereapy
|
|
US7415359B2
(en)
|
2001-11-02 |
2008-08-19 |
Gene Network Sciences, Inc. |
Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
|
|
AU2003218600C1
(en)
|
2002-03-26 |
2009-12-17 |
Zensun (Shanghai) Science & Technology Co., Ltd. |
ERBB3 based methods and compositions for treating neoplasms
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
|
US20040132097A1
(en)
|
2002-06-19 |
2004-07-08 |
Bacus Sarah S. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
EP1517921B1
(en)
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
ES2246191T1
(es)
|
2002-12-11 |
2006-02-16 |
Ventana Medical Systems, Inc. |
Metodo para predecir la respuesta a la terapia dirigida a her2.
|
|
WO2004087887A2
(en)
|
2003-04-01 |
2004-10-14 |
Monogram Biosciences, Inc. |
Intracellular complexes as biomarkers
|
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
EP1664716A4
(en)
|
2003-08-15 |
2008-08-13 |
Smithkline Beecham Corp |
CANCER BIOMARKERS
|
|
US8554486B2
(en)
|
2004-02-20 |
2013-10-08 |
The Mathworks, Inc. |
Method, computer program product, and apparatus for selective memory restoration of a simulation
|
|
PT1733056E
(pt)
|
2004-03-31 |
2013-08-29 |
Gen Hospital Corp |
Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
|
|
JP2007536254A
(ja)
|
2004-05-05 |
2007-12-13 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
|
ES2553264T3
(es)
|
2004-05-27 |
2015-12-07 |
The Regents Of The University Of Colorado |
Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
|
|
US7794960B2
(en)
|
2004-06-04 |
2010-09-14 |
Glaxosmithkline Llc |
Predictive biomarkers in cancer therapy
|
|
AU2005271523B2
(en)
|
2004-08-03 |
2011-09-15 |
Dyax Corp. |
hk1-binding proteins
|
|
RU2410438C2
(ru)
|
2004-08-06 |
2011-01-27 |
Дженентек, Инк. |
Анализы и способы, использующие биомаркеры
|
|
JP2008532476A
(ja)
|
2004-08-12 |
2008-08-21 |
ダイアックス コーポレーション |
複合結合タンパク質
|
|
WO2006044378A2
(en)
|
2004-10-12 |
2006-04-27 |
University Of Iowa Research Foundation |
Rapid computational identification of targets
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
US20060121044A1
(en)
|
2004-12-07 |
2006-06-08 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
|
US7862995B2
(en)
|
2004-12-10 |
2011-01-04 |
Targeted Molecular Diagnostics |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
|
|
EP1853309A4
(en)
|
2005-02-23 |
2008-10-22 |
Merrimack Pharmaceuticals Inc |
BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
|
|
WO2006096861A2
(en)
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
|
US20090061422A1
(en)
|
2005-04-19 |
2009-03-05 |
Linke Steven P |
Diagnostic markers of breast cancer treatment and progression and methods of use thereof
|
|
US20090298061A1
(en)
|
2005-07-29 |
2009-12-03 |
Siemens Healthcare Diagnostics Inc. |
Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy
|
|
WO2007041502A2
(en)
|
2005-09-30 |
2007-04-12 |
Monogram Biosciences |
Methods for determining responsiveness to cancer therapy
|
|
NZ566387A
(en)
|
2005-10-05 |
2010-05-28 |
Astrazeneca Uk Ltd |
Method to predict or monitor the response of a patient to an ErbB receptor drug by screening for mutations in an ErbB receptor
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7908091B2
(en)
|
2006-03-17 |
2011-03-15 |
Prometheus Laboratories Inc. |
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
|
|
EP2049568A2
(en)
|
2006-04-07 |
2009-04-22 |
Københavns Universitet |
Erbb receptor-derived peptide fragments
|
|
WO2007130677A2
(en)
|
2006-05-05 |
2007-11-15 |
Yale University |
Use of subcellular localization profiles as prognostic or predictive indicators
|
|
CA2657324A1
(en)
|
2006-07-13 |
2008-01-17 |
Yale University |
Methods for making cancer prognoses based on subcellular localization of biomarkers
|
|
JPWO2008032876A1
(ja)
*
|
2006-09-15 |
2010-01-28 |
学校法人東海大学 |
Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
|
|
US20100178651A1
(en)
|
2006-11-03 |
2010-07-15 |
Christos Hatzis |
Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
|
|
US20100047829A1
(en)
|
2006-11-28 |
2010-02-25 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
|
US7825127B2
(en)
|
2006-12-28 |
2010-11-02 |
Takeda Pharmaceutical Company, Limited |
Method for treating cancer
|
|
PL2129396T3
(pl)
|
2007-02-16 |
2014-02-28 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
NZ581201A
(en)
|
2007-05-11 |
2012-05-25 |
Enzon Pharmaceuticals Inc |
Rna antagonist compounds for the modulation of her3
|
|
US20090054051A1
(en)
|
2007-08-22 |
2009-02-26 |
James Cavallo |
Attachable Headset for Portable Device
|
|
EA022201B1
(ru)
|
2008-04-11 |
2015-11-30 |
Мерримак Фармасьютикалз, Инк. |
Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
|
|
KR20110044905A
(ko)
*
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
SG178509A1
(en)
|
2009-08-21 |
2012-04-27 |
Merrimack Pharmaceuticals Inc |
Antibodies against the ectodomain of erbb3 and uses thereof
|
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
US8895001B2
(en)
|
2010-03-11 |
2014-11-25 |
Merrimack Pharmaceuticals, Inc. |
Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
US8877687B2
(en)
|
2010-04-26 |
2014-11-04 |
Merrimack Pharmaceuticals |
Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
|
|
BR112013000651A2
(pt)
|
2010-07-09 |
2016-05-31 |
Exelixis Inc |
combinações de inibidores de cinase para o tratamento de câncer.
|
|
FR2963868B1
(fr)
|
2010-08-11 |
2012-09-28 |
Valeo Systemes Thermiques |
Echangeur de chaleur comprenant un element chauffant serigraphie
|
|
JP2014500278A
(ja)
|
2010-12-10 |
2014-01-09 |
メリマック ファーマシューティカルズ インコーポレーティッド |
二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
|
|
WO2012116317A2
(en)
|
2011-02-24 |
2012-08-30 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
AU2012229147B2
(en)
*
|
2011-03-11 |
2015-12-24 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
|
|
US20150231238A1
(en)
|
2011-03-15 |
2015-08-20 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to erbb pathway inhibitors
|
|
KR20140138353A
(ko)
|
2011-04-19 |
2014-12-03 |
메리맥 파마슈티컬즈, 인크. |
단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
|
|
CN103596592A
(zh)
|
2011-05-06 |
2014-02-19 |
梅里麦克制药股份有限公司 |
用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
|
|
WO2012177440A1
(en)
|
2011-06-24 |
2012-12-27 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
|
|
US20140248280A1
(en)
|
2011-06-30 |
2014-09-04 |
Sanofi |
Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
|
|
AU2012294326A1
(en)
*
|
2011-08-10 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
|
|
KR20140148412A
(ko)
|
2012-04-02 |
2014-12-31 |
메리맥 파마슈티컬즈, 인크. |
단일특이적 및 이중특이적인 항-igf-1r 및 항-erbb3 항체의 용량 및 투여
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
CA2975829A1
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|